Codexis (CDXS) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Codexis Reports First Quarter 2021 Financial Results
May 6, 2021 4:05 PM EDTTotal Revenue up 23% and Product Revenue Doubles Year over Year
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.
Codexis growth drivers are continuing to accelerate, and we began 2021 with strong momentum, especially in higher margin product sales within our Performance Enzymes segment, said John Nicols, Codexis President and CEO. Our Life Science Tools business continues to grow rapidly, with initial... More
